These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32308425)

  • 1. Long Noncoding RNA SOCS2-AS Promotes Leukemogenesis in FLT3-ITD+ Acute Myeloid Leukemia Through miRNA-221.
    Zhang R; Huo CH
    Onco Targets Ther; 2020; 13():2925-2934. PubMed ID: 32308425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3 affects FLT3-ITD+ acute myeloid leukemia by mediating autophagy by regulating PSMA3-AS1 stability.
    Wu S; Weng S; Zhou W; Chen Y; Liu Z
    Cell Cycle; 2023 May; 22(10):1232-1245. PubMed ID: 37088992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
    Janke H; Pastore F; Schumacher D; Herold T; Hopfner KP; Schneider S; Berdel WE; Büchner T; Woermann BJ; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Polzer H
    PLoS One; 2014; 9(3):e89560. PubMed ID: 24608088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
    Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
    Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
    Qu S; Liu B; Guo X; Shi H; Zhou M; Li L; Yang S; Tong X; Wang H
    Cancer; 2014 Jul; 120(14):2130-41. PubMed ID: 24737397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.
    Sueur G; Boutet A; Gotanègre M; Mansat-De Mas V; Besson A; Manenti S; Bertoli S
    Sci Rep; 2020 Feb; 10(1):1906. PubMed ID: 32024878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
    Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
    J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
    Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
    Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
    Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.
    Wang LN; Tang YL; Zhang YC; Zhang ZH; Liu XJ; Ke ZY; Li Y; Tan HZ; Huang LB; Luo XQ
    Leuk Lymphoma; 2017 Oct; 58(10):2426-2438. PubMed ID: 28276286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
    Wallace JA; Kagele DA; Eiring AM; Kim CN; Hu R; Runtsch MC; Alexander M; Huffaker TB; Lee SH; Patel AB; Mosbruger TL; Voth WP; Rao DS; Miles RR; Round JL; Deininger MW; O'Connell RM
    Blood; 2017 Jun; 129(23):3074-3086. PubMed ID: 28432220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.
    Fang DD; Zhu H; Tang Q; Wang G; Min P; Wang Q; Li N; Yang D; Zhai Y
    Transl Oncol; 2022 Jan; 15(1):101244. PubMed ID: 34710737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers.
    Dellomo AJ; Abbotts R; Eberly CL; Karbowski M; Baer MR; Kingsbury TJ; Rassool FV
    Transl Oncol; 2022 Jan; 15(1):101283. PubMed ID: 34808460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA; Kazi JU; Rönnstrand L
    Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
    Fathi AT; Arowojolu O; Swinnen I; Sato T; Rajkhowa T; Small D; Marmsater F; Robinson JE; Gross SD; Martinson M; Allen S; Kallan NC; Levis M
    Leuk Res; 2012 Feb; 36(2):224-31. PubMed ID: 21802138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
    Leischner H; Albers C; Grundler R; Razumovskaya E; Spiekermann K; Bohlander S; Rönnstrand L; Götze K; Peschel C; Duyster J
    Blood; 2012 Apr; 119(17):4026-33. PubMed ID: 22411868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.